Institut Pasteur Korea has inked a two-year partnership with Thermo Fisher Scientific to co-develop reagents and services for use with its PhenomicID platform, IP-K said this week.
The approach uses high-content, genome-wide visual arrays to identify drug targets in live cellular disease models. The multi-tiered program involves technology improvement, technology expansion, and pilot drug-target pair studies, IP-K said.
By screening with small interfering RNA libraries, the PhenomicID platform can identify genes that alter drug sensitivity in the cellular disease model, providing a way to determine molecular targets, according to the institute.
Working with Thermo Scientific's Dharmacon RNAi tools and its expertise in high-throughput genome-wide RNAi screening will become "applicable in a wide variety of biological models," Veronica Soloveva, director of the Center of Core Technologies at IP-K, said in a statement.
IP-K was founded near Seoul in 2004 as a partnership between the Institut Pasteur in Paris and the Korea Institute of Science and Technology. It uses array-based high content imaging to extract robust and specific RNAi data sets, providing a means to standardize whole-genome RNAi screening.
IP-K will combine this technology with Dharmacon RNAi platforms to develop an optimized, ready-to-use tool that can identify drug targets and potentially fill a key unmet need in the global scientific community.
"IP-K’s Phenomic array technology enables profiling of well-defined RNAi responses by imaging live cells in multiple parameters simultaneously," according to IP-K CEO Ulf Nehrbass. "In a genome screening setup, this allows us to discern an effect of interest from non-specific background in a highly reliable fashion."
Devin Leake, director of research and development for Thermo Fisher's genomic product division, added that integrating Dharmacon products and services with PhenomicID "will provide an extremely effective 'plug-and-play' solution for use in academic, biotech, and pharmaceutical labs for rapid identification of target compounds."
If the initial phases of the multi-year collaboration yield useable findings, the partners said they will pursue additional collaborations.
Have topics you'd like to see covered in BioArray News? Contact the editor at jpetrone [at] genomeweb [.] com.